SCHEDULE 13G/A: Venrock Healthcare Capital Partners Maintains 11.1% Stake in Oruka Therapeutics, Files Amended Beneficial Ownership Report

Venrock Healthcare Capital Partners and its affiliated entities have filed an amended Schedule 13G, confirming their continued beneficial ownership of 11.1% of Oruka Therapeutics, Inc.'s common stock.

Summary

• The filing is an Amendment No. 2 to a Schedule 13G, updating the beneficial ownership stake of a group of investors in Oruka Therapeutics, Inc.
• The reporting group, led by Venrock Healthcare Capital Partners, collectively beneficially owns 4,148,428 shares of Oruka Therapeutics' common stock.
• This ownership represents 11.1% of the company's total common stock outstanding as of February 15, 2025, which was reported by the Issuer as 37,440,510 shares.
• The holdings include both direct common stock and pre-funded warrants, though the pre-funded warrants contain a 'Beneficial Ownership Blocker' that prevents their exercise if it would result in ownership exceeding 9.99% of the outstanding common stock.
• The reporting persons are currently prohibited from exercising these pre-funded warrants due to the aforementioned blocker provision.
• The filing confirms that the securities were not acquired and are not held for the purpose of changing or influencing the control of Oruka Therapeutics, Inc., other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 6

Explanation: The filing indicates a continued significant stake by a major institutional investor, which is generally a positive signal of confidence. However, it is a routine compliance filing and does not contain new operational or financial performance data from the company itself.

Positives

• The continued significant investment by Venrock Healthcare Capital Partners, a prominent healthcare investor, in Oruka Therapeutics, Inc. suggests ongoing confidence in the company's prospects.
• The reporting group maintains a substantial 11.1% stake, demonstrating a notable long-term commitment to the company.

Negatives

• The pre-funded warrants held by the reporting persons cannot be fully exercised due to a beneficial ownership blocker, which limits their immediate ability to increase their stake beyond 9.99% of outstanding common stock through these specific instruments.

Risks

• The 'Beneficial Ownership Blocker' provision within the pre-funded warrants restricts the reporting persons from exercising these warrants if it would cause their aggregate ownership to exceed 9.99% of Oruka Therapeutics' common stock outstanding, thereby limiting their flexibility to increase their direct common stock holdings from these instruments.

Future Outlook

The document does not contain any forward-looking statements or guidance from Oruka Therapeutics, Inc. regarding its future operations or financial performance. It is solely a disclosure of beneficial ownership by an investor group.

Industry Context

This filing highlights the continued significant investment by Venrock Healthcare Capital Partners, a well-known venture capital firm specializing in healthcare, in Oruka Therapeutics, Inc. This indicates sustained institutional interest in the biotechnology and therapeutics sector, particularly in companies like Oruka Therapeutics.

Related Party Transactions

• The filing details the relationships within the reporting group, including Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh, who are members of a group for the purposes of this Schedule 13G. VHCP Management III is the general partner of VHCP III and manager of VHCP Co-Investment III. VHCP Management EG is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCP Management III and VHCP Management EG.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holding, which can influence market perception and investor confidence.
• Company Management: Awareness of a large, passive institutional investor group maintaining a substantial stake.

Key Dates

Keywords

Oruka Therapeutics, Venrock Healthcare Capital Partners, Schedule 13G/A, beneficial ownership, common stock, pre-funded warrants, institutional investment, SEC filing, biotechnology, therapeutics